Immunofluorescent immunohistochemistry (IHC-IF) staining of pSTAT3 and pSRC on these tumor slices showed that STAT3 activity and SRC activity were dramatically downregulated by Niraparib treatment (Figure 4C). This evidence concerns the gene STAT3 and neoplasm.